Singapore markets close in 3 hours 23 minutes

Zentalis Pharmaceuticals, Inc. (ZNTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.9500-0.3400 (-7.93%)
At close: 04:00PM EDT
3.9700 +0.02 (+0.51%)
After hours: 06:19PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.2900
Open4.2800
Bid3.9400 x 200
Ask4.0000 x 200
Day's range3.9100 - 4.3700
52-week range3.2700 - 29.0300
Volume794,183
Avg. volume1,430,580
Market cap280.502M
Beta (5Y monthly)1.71
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on July 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 40,875 shares of the Company’s common stock to five newly hired empl

  • GlobeNewswire

    Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

    FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today anno

  • GlobeNewswire

    Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

    NEW YORK and SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Zentalis management is scheduled to participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on June 5, 2024, at 4:00 p.m. ET. Access to a live webcast of this event,